| Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference |
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Q1 2025 Earnings Call Transcript |
Pulmonx Corporation (NASDAQ:LUNG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Laine Morgan - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-01 00:25:24 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates |
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.36 per share a year ago. |
zacks.com |
2025-04-30 23:10:36 |
Czytaj oryginał (ang.) |
| Pulmonx Reports First Quarter 2025 Financial Results |
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. |
globenewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER |
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. |
prnewswire.com |
2025-04-11 13:00:00 |
Czytaj oryginał (ang.) |
| EDAP Appoints Glen French to Board of Directors |
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript |
Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-19 21:40:15 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates |
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.36 per share a year ago. |
zacks.com |
2025-02-19 20:20:22 |
Czytaj oryginał (ang.) |
| Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results |
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day |
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. |
globenewswire.com |
2025-02-13 18:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 |
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. |
globenewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect? |
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-21 12:56:19 |
Czytaj oryginał (ang.) |
| Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference |
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema. Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Ze. |
businesswire.com |
2024-11-19 11:00:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Present at the Stifel 2024 Healthcare Conference |
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. |
globenewswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-05 12:56:07 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates |
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago. |
zacks.com |
2024-10-30 21:25:19 |
Czytaj oryginał (ang.) |
| Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024 |
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. |
globenewswire.com |
2024-10-16 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024 |
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- |
globenewswire.com |
2024-09-09 20:05:00 |
Czytaj oryginał (ang.) |
| AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 |
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego. |
prnewswire.com |
2024-09-09 13:00:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference |
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. |
globenewswire.com |
2024-08-29 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference |
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET. |
globenewswire.com |
2024-08-22 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript |
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-01 02:33:13 |
Czytaj oryginał (ang.) |
| Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates |
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago. |
zacks.com |
2024-07-31 22:51:07 |
Czytaj oryginał (ang.) |
| Pulmonx Reports Second Quarter 2024 Financial Results |
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. |
globenewswire.com |
2024-07-31 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference |
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET. |
globenewswire.com |
2024-07-29 20:05:00 |
Czytaj oryginał (ang.) |
| Pulmonx: Low Bar For Q2 Earnings |
New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses. |
seekingalpha.com |
2024-07-21 13:00:00 |
Czytaj oryginał (ang.) |
| Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024 |
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. |
globenewswire.com |
2024-07-10 20:05:00 |
Czytaj oryginał (ang.) |
| 5 Medical Info Systems Stock to Buy for a Stable Portfolio |
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB. |
zacks.com |
2024-06-24 13:20:46 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3% |
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-05-22 14:56:05 |
Czytaj oryginał (ang.) |
| FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif. |
prnewswire.com |
2024-05-16 22:46:00 |
Czytaj oryginał (ang.) |